DataSheet_2.pdf

Abstract

Immune characteristics were reported correlated to benefit of neoadjuvant chemotherapy (NAC) in breast cancer, yet integration of comprehensive genomic alterations and T cell receptors (TCR) to predict efficacy of NAC need further investigation. This study simultaneously analyzed TMB (Tumor Mutation Burden), TCRs, and TILs (tumor infiltrating lymphocyte) in breast cancers receiving NAC. The next generation sequencing technology-based analysis of genomic alteration and TCR repertoire in paired breast cancer samples before and after NAC in a prospective cohort (n=22). Fluorescent multiplex immunohistochemistry was used to stain CD4, CD8, PD1, TIM3, and cytokeratins simultaneously in those paired samples. TMB in pretreatment tumor tissues and TCR diversity index are higher in non-pCR patients than in pCR patients (10.6 vs 2.3；P=0.043) (2.066 vs 0.467；P=0.010). TMB and TCR diversity index had linear correlation (y=5.587x-0.881; r=0.522，P=0.012). Moreover, infiltrating T cells are significantly at higher presence in pCR versus non-pCR patients. Dynamically, the TMB reduced significantly after therapy in non-pCR patients (P=0.010) but without TCR index change. The CDR3 peptide AWRSAGNYNEQF is the most highly expressed in pre-NAC samples of pCR patients and in post-NAC samples of non-pCR patients. In addition to pCR, high clonality of TCR, high level of CD8+ expression are associated with disease-free survival (DFS). TCR index and TMB have significant interaction and may guide neo-adjuvant treatment in operable breast cancers. Response to NAC in tumors with high TCR clonality may be attributable to high infiltration and expansion of tumor-specific CD8 positive effector cells.